ACRS analyst estimates
Aclaris Therapeutics (ACRS) analyst ratings, the average price target and its range, and every firm's latest call.
ACRS analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 28, 2026 | Craig-Hallum | Aclaris Therapeutics price target lowered to $9 from $10 at Craig-Hallum | $9.00 |
| Sep 1, 2026 | Canaccord Genuity | Aclaris Therapeutics initiated with a Buy at Canaccord | $10.00 |
| May 5, 2026 | Guggenheim | Aclaris Therapeutics initiated with a Buy at Guggenheim | $12.00 |
| May 5, 2026 | Piper Sandler | Aclaris Therapeutics price target raised to $11 from $7 at Piper Sandler | $11.00 |
| Apr 29, 2026 | Wedbush | Aclaris Therapeutics price target raised to $10 from $8 at Wedbush | $10.00 |
| Apr 16, 2026 | UBS | Aclaris Therapeutics initiated with an Outperform at Oppenheimer | $10.00 |
| Jan 30, 2026 | Craig-Hallum | Craig-Hallum bullish on Aclaris Therapeutics, initiates with a Buy | $10.00 |
| Nov 19, 2024 | Jefferies | Jefferies Upgrades Aclaris Therapeutis (ACRS) to Buy | $7.00 |
| Nov 19, 2024 | BTIG | BTIG Upgrades Aclaris Therapeutis (ACRS) to Buy | $8.00 |
| Nov 6, 2024 | Stifel Nicolaus | Aclaris Therapeutis (ACRS) PT Raised to $3 at Stifel | $3.00 |
| Dec 1, 2022 | Goldman Sachs | Goldman Sachs Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $25 | $25.00 |
- 7 firms rate ACRS: 7 buy, 0 hold, 0 sell.
- The average price target is $9.50 from 2 analysts, from $9.00 to $10.00.
Updated 2026-11-07 11:52 UTC